TLF
Target Lesion Failure
The efficacy profile of EluNIR remains strong for a duration of 1 to 2 years when compared to other top-performing drug-eluting stents. EluNIR presents outstanding clinical results with a low TLF of 7.0% at 2 years1.
*January 2020 | Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes From the BIONICS and NIREUS Trials. Read Article
*January 2020 | Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes From the BIONICS and NIREUS Trials. Read Article
MI
Myocardial Infarction
EluNIR shows similar rates of MI compared to other top drug-eluting stents, with an incidence of 5.0% at 2 years1.
ST
Stent Thrombosis Definite/
Probable
The EluNIR was found non-inferior to Resolute Integrity in a broad, less selected ‘more comers’ population with 0.4% and 0.5% at 1 and 2 years respectively.2.
*January 2020 | Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes From the BIONICS and NIREUS Trials. Read Article
*January 2020 | Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes From the BIONICS and NIREUS Trials. Read Article
In Stent
Late Loss
Cumulative Distribution Function
EluNIR was found non-inferior to Resolute Integrity in a broad, less selected ‘more comers’ population with 0.04mm in-stent late-loss at 6 months.
EluNIR’s comprehensive clinical program was conducted in the USA, EU, Israel and Japan with thousands of patients
